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Abstract 
Background: The Gaucher Investigative Therapy Evaluation is a national clinical cohort of 250 patients aged 
5–87 years with Gaucher disease in the United Kingdom—an ultra-rare genetic disorder. To inform clinical decision-
making and improve pathophysiological understanding, we characterized the course of Gaucher disease and 
explored the influence of costly innovative medication and other interventions. Retrospective and prospective clinical, 
laboratory and radiological information including molecular analysis of the GBA1 gene and comprising > 2500 vari-
ables were collected systematically into a relational database with banking of collated biological samples in a central 
bioresource. Data for deep phenotyping and life-quality evaluation, including skeletal, visceral, haematological and 
neurological manifestations were recorded for a median of 17.3 years; the skeletal and neurological manifestations are 
the main focus of this study.
Results: At baseline, 223 of the 250 patients were classified as type 1 Gaucher disease. Skeletal manifestations 
occurred in most patients in the cohort (131 of 201 specifically reported bone pain). Symptomatic osteonecrosis and 
fragility fractures occurred respectively in 76 and 37 of all 250 patients and the first osseous events occurred signifi-
cantly earlier in those with neuronopathic disease. Intensive phenotyping in a subgroup of 40 patients originally 
considered to have only systemic features, revealed neurological involvement in 18: two had Parkinson disease and 16 
had clinical signs compatible with neuronopathic Gaucher disease—indicating a greater than expected prevalence 
of neurological features. Analysis of longitudinal real-world data enabled Gaucher disease to be stratified with respect 
to advanced therapies and splenectomy. Splenectomy was associated with an increased hazard of fragility fractures, 
in addition to osteonecrosis and orthopaedic surgery; there were marked gender differences in fracture risk over time 
since splenectomy. Skeletal disease was a heavy burden of illness, especially where access to specific therapy was 
delayed and in patients requiring orthopaedic surgery.
Conclusion: Gaucher disease has been explored using real-world data obtained in an era of therapeutic transforma-
tion. Introduction of advanced therapies and repeated longitudinal measures enabled this heterogeneous condition 
to be stratified into obvious clinical endotypes. The study reveals diverse and changing phenotypic manifestations 
with systemic, skeletal and neurological disease as inter-related sources of disability.
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Background
Gaucher disease is an autosomal recessive disorder of 
sphingolipid metabolism caused by catalytic deficiency 
of lysosomal acid β-D-glucosylceramidase (ß-glucocer-
ebrosidase; EC 3.2.1.45) [1, 2]. Impaired lysosomal recy-
cling of ß-glucosylceramides leads to over-production 
of ß-glucosylsphingosine. This ultra-rare inborn error 
is principally caused by biallelic mutations in the GBA1 
gene located on chromosome 1q22 [2] and is most fre-
quent in Ashkenazi Jews and occurs in small isolated 
populations in North Sweden and Brazil [3–5].
A convenient, but imperfect clinical classification 
of Gaucher disease, recognises three principal sub-
types: type 1 (GD1, OMIM 230800, chronic non-
neuronopathic), type 2 (GD2, OMIM 230900, acute 
neuronopathic) and type 3 (GD3, OMIM 231000, chronic 
neuronopathic) diseases [2]. This operational classifica-
tion is summarized in Additional file  1: Table  S1. How-
ever, a striking feature in all subtypes, is the heterogeneity 
of this disease in the age and rate of onset, as well as the 
widespread effects. Especially in the type 1 disease, adults 
as well as children can have only mild symptoms or be 
asymptomatic. Marked differences of disease expression 
are seen between affected siblings and clinically discord-
ant monozygotic twins suggest not only the existence of 
modifier genes but complex interactions with environ-
mental factors [2, 6–9].
Evidence of disease is detectable in the bone marrow 
and macrophage-rich organs such as the spleen and liver 
where dynamic recycling of membrane sphingolipids 
derived from blood cells occurs. Glycosphingolipid accu-
mulation in engorged, often multinuclear histiocytes, 
generates the pathognomonic Gaucher cell [6]. With the 
exception of the nervous system, functional disturbances 
and tissue injury occur at sites where macrophages are 
most abundant, such as the skeleton (marrow), spleen, 
liver and sometimes the lung [2, 6, 8, 10]. Systemic mani-
festations reflect combinations of bone marrow and 
visceral involvement due to activation of histiocytes 
with local inflammatory responses; fibrosis with scar-
ring may follow. In patients with symptomatic disease, a 
sustained inflammatory state is accompanied by release 
of cytokines and hepatosplenomegaly and in children, 
delayed growth and puberty [11–13]. In the absence of 
specific therapy, massive splenomegaly complicated by 
cytopenias may necessitate splenectomy. Gaucher dis-
ease may impair skeletal development with defective 
modelling, poor mineralization, osteolytic lesions and 
osteonecrosis—the latter mainly occurring at the epi-
physes of long bones. Osteonecrosis may be explained 
by compromised blood flow in the growth plate micro-
vasculature (Fig. 1 and Additional file 2: Fig. S1). It may 
be driven by glucosylceramide-related activation of mac-
rophage-inducible C-type lectin (Mincle) with effects on 
osteocytes [14, 15].
The neurological complications are also not fully 
understood but unlike the pathology in macrophage-
rich tissues, mainly reflect impaired lysosomal recy-
cling of endogenous glucosylceramide derived from the 
membrane turnover in long-lived neural cells although 
perivascular accumulation of pathological storage mac-
rophages in cerebral and cerebellar sub-cortical white 
matter occurs in chronic neuronopathic disease (as in 
Norrbottnian patients). However, neuronophagia with 
microglial satellitosis in the cerebral cortex and dentate 
nucleus occurs with biochemical and ultrastructural evi-
dence of glucosylceramide and psychosine excess, the 
latter apparently correlated with neuronal loss [16, 17]. 
Systematic neuropathological studies after necropsy 
in thirteen patients classified across all three subtypes, 
including those with parkinsonism and dementia (with 
Lewy bodies containing synuclein) in type 1, identified 
distribution of disease uniquely affecting cerebral corti-
cal layers 3 and 5, hippocampal CA2-4, and layer 4b of 
the calcarine cortex correlated with neurological impair-
ment [18]. Prominent neuronal loss occurred in acute 
neuronopathic (type 2) and chronic neuronopathic dis-
ease (type 3) with progressive myoclonic encephalopathy; 
astrogliosis was the only neuropathological finding in 
‘non-neuronopathic’ Gaucher disease.
In resource-rich countries, patients with Gaucher 
disease have access to transformative molecular thera-
pies which address its systemic and skeletal manifesta-
tions. However, in many countries availability of these 
advanced medications is restricted by cost and by the 
practical arrangements associated with high-cost recom-
binant proteins that must be given regularly by slow infu-
sion. Current treatments include recombinant human 
glucosylceramidase modified for preferential targeting to 
macrophages and given intravenously, or oral therapies 
involving small molecules with distinct modes of action 
[8, 19–22]. The full licensed doses for initiating enzyme 
therapy (60 iu/Kg every two weeks) are not universally 
used because of the heterogeneity and the multi-systemic 
nature of Gaucher disease. This is generally accepted by 
regulatory authorities in the context of ‘individualized’ 
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therapy. Once the individual patient response for all 
relevant clinical manifestations is established, dos-
ages and frequency of administration may be adjusted 
with the goal to either maintain already reached opti-
mal parameters for all clinical manifestations or further 
improve those clinical parameters which have not yet 
been normalised. While there is a trend to lower doses 
in resource-poor settings, some insurers/ payers in rela-
tively rich countries challenge costs; where monitoring is 
not optimal or expertise lacking, dosing may not control 
disease in all compartments.
Hitherto, two systemically active oral preparations, 
miglustat and eliglustat, based on the principle of sub-
strate restriction have been approved for type 1 Gaucher 
disease. These molecules can attenuate the biosynthe-
sis of glucosylceramide to allow the residual lysosomal 
digestive function to clear the pathological excess of the 
sphingolipid [23–29]. Targeted enzyme therapy is avail-
able for type 1 and the systemic manifestations of type 3 
Gaucher disease. In the United Kingdom (UK), decisions 
about treatment are determined by expert physicians 
guided by patient preference and local prescribing rules.
The variable course of Gaucher disease and avail-
ability of specific therapies with distinct modes of 
action prompted us to seek a better understanding of 
its response to different interventions. To quantify the 
effects of treatment, we explored data collected dur-
ing long-term real-world delivery of care over several 
decades of specialist practice across the UK and built a 
platform based on repeated measures and in-depth clini-
cal phenotyping. With an engaged national cohort of 
patients attending specialist centres, we collected retro-
spective and prospective data in those with a confirmed 
clinical, biochemical and genetic diagnosis. Funded 
principally by the UK Medical Research Council, the 
Gaucher Investigative Therapy Evaluation (GAUCHE-
RITE), enrolled 250 patients aged 5–87 years. The cohort 
includes patients with all but the most acute neurological 
Fig. 1 Radiographic imaging of skeletal manifestations in Gaucher disease. Generalized osteopaenia and lytic areas in iliac wings (A) and mid shafts 
of both femora (A, B), tibiae (B) and humeri (C). Pathological fractures both upper femora (A). Erlenmeyer flask deformity of both femurs, also known 
as metaphyseal flaring (B). Gross expansion and coarse trabeculation of the left femur (D). Extensive osteonecrosis of the right femoral head, which 
shows marked flattening with complete loss of joint space (E). Prominent thoracic kyphosis and exaggerated lumbar lordosis with minimal lumbar 
curve (F). H-shaped vertebrae of the thoracic spine consistent with osteonecrosis (G)
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forms of the disease (type 2, OMIM 230900 and the spo-
radic lethal perinatal form, OMIM 608013).
Once established, the skeletal and neurological features 
of Gaucher disease become irreversible causes of disabil-
ity: hence these domains were chosen for detailed study. 
Here we report the clinical and radiological character-
istics of the cohort in which the known determinants 
of outcome are recorded: these include clinical severity 
scores and the onset and rate of disease progression in 
the context of different interventions (e.g. splenectomy 
or molecular therapy). With extensive imaging, explora-
tion of potential biomarkers and longitudinally repeated 
in-depth determinations, we have established a data-rich 
analytical platform further to investigate pathogenesis. 
To inform optimal management, the ultimate aim of this 
work is to define therapeutic endotypes of Gaucher dis-
ease. Combined with extensive haematological and bio-
chemical testing, as well as imaging and DXA studies, 




In the UK, treatment for Gaucher disease is available only 
at specialist centres approved by the National Health Ser-
vice (NHS). All patients attending each of the eight NHS 
specialist centres in England (Additional file 1: Table S2) 
were invited to participate. Clinical, radiological and lab-
oratory data, including case report forms and other study 
documents, were securely recorded in the bespoke, web-
based, relational GAUCHERITE database using unique 
identifier numbers for each centre and the individual 
patients attending.
Data were collected at defined intervals and transcribed 
from GAUCHERITE clinical study forms that include 
records of structured physical examinations preceded by 
completion of a dedicated health questionnaire. The clin-
ical interrogation was mainly directed to skeletal events, 
physical manifestations and specialised neurology; 
comorbidities were also captured. Separately, patients or 
carers completed detailed quality-of-life, fatigue, health 
and anxiety questionnaires; specific questions were 
related to growth measures, as well as voice changes 
or breast development, as well as the age at menarche 
and the menopause. All treatments were recorded with 
emphasis on therapies directed to bone disease as well 
as the dosing of, and adherence to, molecular therapies 
administered specifically for Gaucher disease.
As set out in Additional file  1: Table  S3, plasma and 
serum biomarkers have been measured over intervals 
and the data captured—including the tissue-response 
analytes, chitotriosidase activity and the concentration 
of CC chemokine pulmonary and activation-regulated 
chemokine (PARC)/CCL18. From the outset, a tissue 
biobank was developed (curated by FMP, Gaucherite Co-
Principal Investigator). Biological material was collected 
from 238 patients (182 with serial samples) and frozen. 
This resource is suitable for analysis of sphingolipid 
biomarkers, including unacylated metabolites of gluco-
sylceramide; genomic DNA is also retained for future 
analysis in ethically approved research studies.
Study population
Two hundred and fifty patients with a confirmed diag-
nosis of Gaucher disease were enrolled between May 
2015 to October 2017; this pre-set target, included adults 
and children and represents ≈ 85% of all those patients 
known in the UK (< 290). The database was locked in 
July 2018, allowing 0.5–3 years of prospective data to be 
collected and retrospective data from > 2–25  years. The 
patients included those diagnosed with the so-called 
non-neuronopathic (type 1) and chronic neuronopathic 
(type 3) disease variants. Patients likely to die within six 
months, those unable to understand the consent form, 
or those otherwise judged unsuitable by the investiga-
tor, were not recruited. These constitute a group of more 
than 50 known to have died since 1990 with longitudinal 
data also held on the database and shortly to be reported.
Definitive diagnosis of Gaucher disease was based on 
enzymatic assay in leukocytes or skin fibroblasts; this 
was supported by molecular analysis of the GBA1 gene, 
except in one adult patient with a genetically confirmed 
diagnosis of saposin C deficiency (later treated with eli-
glustat). Genotyping was carried out in regional NHS 
diagnostic services by targeted Sanger sequencing using 
GBA1 primers (Transcript: NM_000157.3) for 11 indi-
vidual exons and intron boundaries using Primer3Plus 
to obtain PCR amplification products from all coding 
sequences and those in flanking intronic regions. Con-
ventional nomenclature was used to describe GBA1 
mutations and principally employs a long-established 
protein designation derived from AAC63056.1 [31]; in 
this manuscript, when first describing mutant GBA1 
alleles, the 2016 HGVS nomenclature [32] is also used.
Data collection
Prospective and retrospective clinical data were entered 
into the GAUCHERITE electronic case report form, 
including, for adult patients, medical records held at for-
mer paediatric specialist centres. The median number of 
visits was 26.1 (28.1 ± 17.4, mean ± standard deviation, 
SD) and median follow-up was 17.3  years, range up to 
55 years (16.5 ± 9.2, mean ± SD). One child, aged 5 years, 
had clinical data and investigations entered on enrolment 
but was not further followed up during the study period. 
All these data including archived medical imaging studies 
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(Additional file  1: Table  S3) were anonymised. Regular 
data audits were conducted to ensure quality and com-
pleteness. A detailed description of the parameters col-
lected is set out in the Additional file  1. Saccadic eye 
movements were measured prospectively under separate 
ethical approval in a consented subset of subjects using 
the EyeSeeCam device with a head-mounted camera for 
video-oculography [33, 34].
Fragility fracture was defined according to the World 
Health Organization [35] definition of low-impact 
fractures (see Additional file  1). The term “Sympto-
matic Osteonecrosis”, as used here, represents an event 
recorded in the clinical record by the treating physician 
as osteonecrosis or avascular necrosis and supported by a 
description of characteristic symptoms; radiological con-
firmation was not required for this purpose.
Statistical analysis
Unless otherwise stated, baseline parameters are 
described at the time of enrolment into GAUCHERITE 
for all patients by reporting frequencies and proportions 
for categorical variables and summary statistics for con-
tinuous variables.
Time-to-event outcomes and repeated events data 
were described using Cox cumulative hazard functions 
and Andersen-Gill methods, respectively. Time origin for 
these analyses depended on the outcome and the specific 
research questions. Subjects were not included if relevant 
dates were not recorded. For the purpose of these analy-
ses, database lock was July 31 2018. To study the effect of 
age at initiation of enzyme therapy or substrate reduction 
therapy on time from presentation with Gaucher dis-
ease to bone manifestation, we initially examined six age 
categories (under 10, 10–19, 20–29, 30–39, 40–49, and 
50 years or older). Hazard ratios among the two younger 
groups and among the four older age groups was similar. 
Thus, for analytical purposes, age at initiation of specific 
treatment was stratified into two categories: younger 
than 20 years, and greater or equal to 20 years. Statistical 
significance was assessed at the 5% significance level after 
accounting for the possibility of model misspecification 
using robust standard errors; where used, 95% confidence 
limits are shown in parentheses. The STATA SE v14.2 
and R software programme was used for all analyses.
Results
Population demographics and disease characteristics
Table 1 shows the baseline characteristics of the cohort: 
the population is stratified by age (children, up to the 
age of 18  years; adults, 18  years or older) and the ini-
tially assigned subtype of Gaucher disease (type 1 
and 3). Of the 250 patients (128 male and 122 female, 
median age 46  years, range: 5–87), 223 had a clinical 
diagnosis of non-neuronopathic type 1 Gaucher dis-
ease (120 males and 103 females; median age 48 years, 
range: 5–87) and 27 of neuronopathic type 3 Gaucher 
disease (8 male and 19 female; median age 23  years, 
range 5–60), as determined by the participating physi-
cian. Of note, 26 patients (13 male and 13 female; 17 
type 1 and 9 type 3) were under 18 years of age when 
enrolled. Of the patients with type 1 Gaucher disease, 
7 had Parkinson disease (median age of this diagnosis 
52 years, range: 35–70). Eighty-five patients had a fam-
ily history of Parkinson disease and/or dementia.
Forty-three patients (17%) stated that they were 
of Jewish descent; no patient of Jewish ancestry had 
neuronopathic (type 3) Gaucher disease. No other 
ethnic information was formalized for classification. 
Despite the rarity of the condition, overt consanguin-
ity was identified in only 18 (7%) of the parents. Onset 
of symptoms or signs attributed to Gaucher disease 
had occurred earlier in patients with type 3 disease 
(median at 1  year, range: < 1–16) compared with those 
assigned to the type 1 category (median age 13  years, 
range: < 1–72). The most frequent presenting manifes-
tation was an enlarged abdomen (15%), often with a 
bleeding tendency (17%). Other manifestations are set 
out in Table 1.
Most patients were diagnosed in childhood: the 
median age was 16 (range: < 1–73) years. Those with type 
3 disease were much younger at diagnosis (median age 
2 years, range: < 1–16) than type 1 (median age 20 years, 
range: < 1–73). The ratio of females to males in this group 
is 2.4 but does not differ significantly from a random 
sample (χ2 1.53 with Yates correction, p = 0.216). Of 
note, 13 (5%) patients did not give a history of Gaucher-
related symptoms: 8 were diagnosed as a result of fam-
ily screening after an index case was identified; 4 were 
identified incidentally (test performed for a reason unre-
lated directly to health) and in one patient in response 
to other manifestations not considered to be Gaucher-
related. None was identified by prenatal diagnosis or 
newborn screening. Although the clinical diagnosis in 
all cases was suspected by a combination of features and 
acid β-glucosidase assay is now more often requested, 
historically the most common primary diagnostic indica-
tor was bone marrow biopsy (29%). Confirmation of the 
suspected diagnosis in all cases required either definitive 
measurement of enzyme activity (typically in periph-
eral blood leukocytes) or molecular analysis of GBA1 in 
genomic DNA. To detect recombinant alleles and those 
harbouring deletions such as the del55 bp, as well as 
novel GBA1 variants, sequencing of the GBA1 locus in 
genomic DNA was undertaken in the entire cohort (see 
methods and below). The procedure followed standard 
clinical sequencing practice to ensure that the functional 
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Table 1 Clinical characteristics of the GAUCHERITE cohort and subgroups at recruitment
Variables Categories* Entire cohort 
(N = 250) [%]
Children
(N = 26) [%]
Adults
(N = 224) [%]
Gaucher Type 
1 (N = 223) 
[%]
Gaucher Type 
3 (N = 27) [%]
Gender Male 128 [51] 13 [50] 115 [51] 120 [54] 8 [30]
Female 122 [49] 13 [50] 109 [49] 103 [46] 19 [70]
Recruitment age (y) Mean age ± SD 44 ± 19 11 ± 4 48 ± 16 46 ± 18 26 ± 16
Median (range) 46 (5–87) 11 (5–17.8) 49 (18.7–87) 48 (5–87) 23 (5–60)
Jewish descent Yes 43 [17] 1 [4] 42 [19] 43 [19] –
No 207 [83] 25 [96] 182 [81] 180 [81] 27 [100]
Consanguinity Yes 18 [7] 2 [8] 16 [7] 9 [4] 9 [33]
No 232 [93] 24 [92] 208 [93] 214 [96] 18 [67]
Age at symptom onset (y) Mean age ± SD 16 ± 15 3 ± 2 18 ± 15 18 ± 15 3 ± 4
Median (range) 11 (0–72) 2 (0–8) 13 (0–72) 13 (0–72) 1 (0–16)
No symptoms 13 – 13 12 1
Unknown 5 – 5 4 1
First symptoms Enlarged abdomen 37 [15] 6 [23] 31 [14] 28 [12.5] 9 [33]
Enlarged abdomen plus other 
symptoms
67 [27] 8 [31] 59 [26] 56 [25] 11 [40]
Easy bleeding/bruising 34 [14] 1[4] 33 [15] 34 [15] –
Easy bleeding/bruising plus other 
symptoms
36 [14] 4 [15] 32 [14] 35 [16] 1 [4]
Fatigue 9 [4] – 9 [4] 9 [4] –
Fatigue plus other symptoms 6 [2] – 6 [3] 6 [3] –
Bone disease 15 [6] – 15 [7] 15 [7] –
Other non-classical GD symp-
toms
32 [13] 7 [27] 25 [11] 28 [12.5] 4 [15]
No symptoms 13 [5] – 13 [6] 12 [5] 1 [4]
Unknown 1 [< 1] – 1 [< 1] – 1 [4]
Presentation age (y) Mean age ± SD 18 ± 16 3 ± 2 20 ± 16 20 ± 16 3 ± 4
Median (range) 13 (0–72) 2 (0–8) 16 (0–72) 16 (0–72) 2 (0–16)
Missing age 2 – 2 1 1
Age at diagnosis (y) Mean age ± SD 21 ± 17 4 ± 3 23 ± 17 23 ± 17 3 ± 4
Median (range) 16 (0–73) 3 (1–10) 20 (0–73) 20 (0–73) 2 (0–16)
Diagnostic pathway Enzyme assay 21 [8] 7 [27] 14 [6] 17 [8] 4 [15]
GBA-gene sequencing 23 [9] 1 [4] 22 [10] 23 [10] –
Bone marrow histology 71 [29] 3 [11] 68 [30] 68 [30] 3 [11]
Liver histology 12 [5] 2 [8] 10 [5] 11 [5] 1 [4]
Spleen histology 11 [4] – 11 [5] 9 [4] 2 [7]
Other histology 1 [< 1] – 1 [< 1] 1 [< 1] –
Combination of these methods 105 [42] 13 [50] 92 [41] 89 [40] 16 [59]
Clinical history 5 [2] – 5 [2] 5 [2] –
Unknown 1 [< 1] – 1 [< 1] – 1 [4]
Parkinson disease Yes 7 [3] – 7 [3] 7 [3] –
Age at diagnosis, years, 
mean ± SD
54 ± 12 – 54 ± 12 54 ± 12 –
Median (range) 52 (35–70) – 52 (35–70) 52 (35–70) –
No 243 [97] 26 [100] 217 [97] 216 [97] 27 [100]
Family history of Parkinson/
dementia
Yes 85 [34] 4 [15] 81 [36] 76 [34] 9 [33]
No 165 [66] 22 [85] 143 [64] 147 [66] 18 [67]
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gene and not the vicinal GBA pseudogene was amplified 
for characterization in isolation.
Complete genomic sequencing identified causal muta-
tions of the GBA1 gene in 248 patients  (Additional 
file  1: Table  S7); one patient harboured two previ-
ously unknown mutant alleles and in one sibling of 
a known patient, no DNA was  available for analysis; 
two mutant PSAP alleles in trans had been determined 
Table 1 (continued)
Variables Categories* Entire cohort 
(N = 250) [%]
Children
(N = 26) [%]
Adults
(N = 224) [%]
Gaucher Type 
1 (N = 223) 
[%]
Gaucher Type 
3 (N = 27) [%]
GBA1 Genotypes N370S/N370S 33 – 33 33 –
L444P/L444P 20 6 14 – 20
R463C/R463C 2 – 2 2 –
W184R/W184R 1 – 1 1 –
N370S/L444P 38 – 38 38 –
N370S/other 106 11 95 106 –
L444P/R463C 12 2 10 11 1
L444P/other 7 2 5 4 3
R463C/other 15 2 13 13 2
Other /other 14 2 12 13 1
Unknown/NA*
* heterozygous PSAP mutations
2 1 1 2 –
Failure to thrive in childhood Yes 65 [26] – 65 [29] 56 [25] 9 [33]
No 141 [56] – 141 [63] 134 [60] 7 [26]
Unknown/NA 44 [18] 26 [100] 18 [8] 33 [15] 11 [41]
Considered shorter than school 
peers
Yes 86 [35] – 86 [38] 77 [34.5] 9 [33]
No 123 [49] – 123 [55] 116 [52] 7 [26]
Unknown/NA 41 [16] 26 [100] 15 [7] 30 [13.5] 11 [41]
Considered themselves under-
weight
Yes 71 [29] – 71 [32] 64 [29] 7 [26]
No 138 [55] – 138 [61] 129 [58] 9 [33]
Unknown/NA 41 [16] 26 [100] 15 [7] 30 [13] 11 [41]
Delayed puberty Yes 54 [22] – 54 [24] 49 [22] 5 [18]
No 148 [59] – 148 [66] 137 [61] 11 [41]
Unknown/NA 48 19] 26 [100] 22 10] 37 [17] 11 [41]
Onset of regular shaving/men-
ses, N
Male 101 [79] – 101 [88] 96 [80] 5 [63]
Years, mean age ± SD 17 ± 2 – 17 ± 2 17 ± 2 20 ± 4
Median (range) 16 (9–26) – 16 (9–26) 16 (9–23) 18 (16–26)
Missing/NA 27 13 14 24 3
Female 100 [82] – 100 [92] 89 [86] 11 [58]
Years, mean age ± SD 14 ± 2 – 14 ± 2 14 ± 2 13 ± 2
Median (range) 14 (6–19) – 14 (6–19) 14 (6–19) 13 (11–16)
Missing/NA 22 13 9 14 8
Menopause, N Yes 51 [42] – 51 [47] 48 [47] 3 [16]
Age occurred years mean ± SD 46 ± 7 – 46 ± 7 46 ± 7 39 ± 10
Median age (range) 47 (26–58) – 47 (26–58) 47 (26–58) 36 (31–51)
HRT status Yes 20 [39] – 20 [39] 18 [38] 2 [67]
No 29 57] – 29 [57] 28 [58] 1 [33]
Missing 2 – 2 2 –
HRT hormone replacement therapy, NA not applicable, SD standard deviation
*Categorical variables are expressed as frequency [percent]. Continuous variables are expressed as mean ± SD and median (range)
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in one adult. The most common GBA1 variant was 
p.Asn409Ser (N370S) followed by p.Leu483Pro (L444P) 
and p.Arg502Cys (R463C), accounting for 42.2, 19.5 
and 3.8 percent of the 498 mutant GBA1 alleles, respec-
tively. Genotype frequencies reflected this distribution: 
33 patients had a homozygous N370S genotype of whom 
a majority but not all stated that they were Jewish (all 
had non-neuronopathic type 1 disease); 20 were L444P 
homozygotes (all with neuronopathic disease); two 
patients were homozygous for R463C. Of the most fre-
quent compound heterozygotes, 38 were N370S/L444P 
and 12 were L444P/R463C. Three of the seven patients 
with Parkinson disease were homozygous for N370S; of 
the other four, one was homozygous for R463C, two were 
N370S/L444P and one had the L444P/R463C compound 
GBA1 genotype. In patients originally classified as having 
type 1 disease, four fifths harboured at least one copy of 
N370S; in those classified as type 3 disease, nearly 90% 
had at least one copy of the recurrent L444P allele. Both 
alleles were present among the 40 patients who were 
neurologically re-evaluated; apart from those related to 
Parkinson disease, no patient habouring the N370S allele 
was found to have neurological signs. In the cohort as 
a whole, recombinant, splice-site, the  RecΔ5 (del55bp) 
and novel mutant alleles, as well as previously described 
double missense mutations in cis (e.g. D409H + H255Q) 
were each identified in several patients (Additional file 1: 
Table S7).
Skeletal manifestations
The skeletal manifestations of Gaucher disease in this 
study cohort were clinically and radiologically diverse 
(Fig. 1, Table 2 and Additional file 2: Fig. S1). Quantifica-
tion of the periodicity and presence or absence of bone 
pain entered into the Zimran Severity Score Index [36] 
was carried out at enrolment in 201 patients. Of these, 
131 suffered pain (chronic in 31 patients, frequent in 
34, occasional in 41, periodicity not stated in 25); pain 
occurred at all ages and only 70 were pain-free. The 
severity of skeletal pain, assessed by using the Gaucher 
Disease Type 1 Severity Scoring System, GD-DS3 [37], 
was recorded in a subset of patients (n = 129), and was 
extreme in two, severe in 14, moderate in 47, mild in 41, 
and was not scored in 25 patients.
Symptomatic osteonecrosis, the most clinically sig-
nificant and disabling skeletal manifestation of Gaucher 
disease, occurred in seventy-six patients. Among these, 
43 had one episode and 33 had two or more episodes. 
Osteonecrosis caused bone pain in 45 or classical acute 
bone crisis in 30 cases, while only one patient had skel-
etal symptoms that were not painful. The median age at 
first episode of osteonecrosis in these 76 patients was 22 
(range 4–64) years: of these, nearly 90% occurred in the 
femur (distal or proximal), 4% occurred in the humeral 
head, 3% in the tibia and 4% at other sites.
Skeletal involvement in Gaucher disease includes 
reduced bone mineral density (BMD) which can be 
detected using dual-energy X-ray absorptiometry (DXA) 
and predisposes to fracture. Although most patients 
had had multiple DXA measurements between pres-
entation and recruitment to the study, DXA determi-
nations ± 24  months from enrolment were available in 
a majority (n = 189 spine; n = 165 hip; n = 77 forearm; 
Table  2). Overall median vertebral bone mineral den-
sity of L1–L4 was 0.982 (range 0.547–1.446) g/cm2. The 
median total hip and femoral neck BMD were 0.924 
(0.600–1.276) and 0.801 (0.464–1.360) g/cm2, respec-
tively. Median forearm density was 0.653 (0.458–0.871) 
g/cm2. Among postmenopausal women and men aged 
50  years and older, 24 had DXA T-scores within the 
healthy reference range, while 34 had T-scores between 
− 1 and − 2.5 that are considered osteopaenic and 23 had 
a T-score of -2.5 or lower—taken to indicate osteopo-
rosis. Among premenopausal women and men younger 
than 50 years, 94 had DXA Z-scores within the expected 
range for age, while 17 had a Z-score of -2.0 or lower and 
thus below the expected range for age.
Sixteen males and 21 females had a history of one or 
more fragility fractures at any site; the median age at 
first fragility fracture was 36 (range 4–78) years. The 
spleen had been removed in twenty-three of the 37. 
Of the total of 79 fragility fractures at recruitment, 
30% had occurred in the spine; 29% in the hip/femur; 
16% were in the ribs; 6% in the wrist and 19% occurred 
elsewhere. As detailed in Table 1, patients with type 3 
disease generally had lower bone density at a younger 
age: those who suffered at least one fragility fracture, 
had their first episode earlier (median age 20  years, 
range: 4–50) than those with type 1 disease with one 
or more fragility fractures (median age 44 years, range: 
13–78 years).
Radiological signs of osteoarthritis and frank osteolytic 
lesions were reported in 105 and 13 patients, respec-
tively. Erlenmeyer flask deformity based on individual 
radiographic assessment was present in 80 out of the 125 
adult patients for whom radiographs of the knee and dis-
tal femur were available for re-analysis. A defining ratio 
between the diameter of the femoral shaft 4 cm from the 
physis to the diameter of the physeal baseline of greater 
than 0.57 was used [38].
Orthopaedic surgery had been undertaken in sixty-
two patients: procedures were mainly carried out for 
joint destruction related to osteonecrosis but surgery 
was also required for fractures.
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Table 2 Bone manifestations and radiological characteristics of the GAUCHERITE cohort and subgroups at recruitment
Variables Categories* Entire cohort 
(N = 250) [%]
Children
(N = 26) [%]
Adults
(N = 224) [%]
Gaucher Type 1 
(N = 223) [%]
Gaucher Type 3 
(N = 27) [%]
History of Fragility 
fracture
Yes 37 [15] – 37 [17] 29 [13] 8 [30]
1 fracture 22 – 22 17 5
 > 1 fracture 15 – 15 12 3
Age at 1st event, 
years, mean ± SD
38 ± 19 – 38 ± 19 42 ± 18 23 ± 16
Median (range) 36 (4–78) – 36 (4–78) 44 (13–78) 20 (4–50)
No 213 [85] 26 [100] 187 [83] 194 [87] 19 [70]
Fracture site Spine 24 – 24 20 4
Hip/Femur 23 – 23 15 8
Ribs 12 – 12 10 2
Wrist 5 – 5 4 1
Other bones 15 – 15 14 1
History of Sympto-
matic Osteonecrosis
Yes 76 [30] – 76 [34] 70 [31] 6 [22]
1 event 43 – 43 39 4
 ≥ 2 events 33 – 33 31 2
Mean age ± SD at 
1st event, years
26 ± 16 – 26 ± 16 26 ± 16 14 ± 2
Median age (range) 22 (4–64) – 22 (4–64) 22 (4–64) 14 (12–16)
Age unknown 4 – 4 2 1
No 174 [70] 26[100] 148 [66] 153 [69] 21 [78]
Symptoms of
Osteonecrosis event
Yes 76 [30] – 76 [34] 70 [31] 6 [22]
Classical acute bone 
crisis
30 – 30 27 3
Pain 45 – 45 42 3
Symptomatic, other 
than pain
1 – 1 1 –
Presence of bone/
joint pain
Yes 131 52] 4 [15] 127 [57] 118 [53] 13 [48]
Continuous/chronic 31 – 31 27 4
Frequently 34 1 33 31 3
Occasional 41 3 38 37 4
Pain periodicity not 
recorded
25 – 25 23 2
No 70 [28] 13 [50] 57 [25] 61 [27] 9 [33]
Unknown 49 [20] 9 [35] 40 [18] 44 [20] 5 [19]
Severity of bone/
joint pain (GD1–DS3 
score)
Yes 129 [52] 4 [15] 125 [56] 116 [52] 13 [48]
Extreme 2 – 2 2 –
Severe 14 – 14 13 1
Moderate 47 1 46 41 6
Mild 41 1 40 39 2
Pain severity not 
recorded
25 2 23 21 4
Unknown 121 [48] 22 [85] 99 [44] 107 [48] 14 [52]
Lytic lesions Yes 13 [5] – 13 [6] 11 [5] 2 [7]
No 237 [95] 26 [100] 211 [94] 212 [95] 25 [93]
Osteoarthritis Yes 105 [42] – 105 47] 100 [45] 5 [19]
No 145 [58] 26 [100] 119[53] 123 55] 22 [81]
Orthopaedic pro-
cedure
Yes 62 [25] – 62 [28] 55 [25] 7 [26]
No 188[75] 26 [100] 162 [72] 168 [75] 20 [74]
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Neuronopathic disease
Of the 27 patients with a diagnosis of chronic neurono-
pathic disease (type 3) at enrolment, the median age was 
23  years (range: 5–60); four were older than 40  years. 
Neuronopathic features had often been detected after 
Gaucher disease was diagnosed: the most common pre-
senting feature was a horizontal saccadic eye movement 
defect, typical of the disorder. After Gaucher disease had 
been diagnosed, formal recognition of the neuronopathic 
manifestations occurred within one year in 17 of the 27 
patients, but in the remaining 10, these manifestations 
remained undocumented for between 2 and 48  years. 
Hepatosplenomegaly was the most frequent present-
ing manifestation, often in association with neurological 
signs, or as an incidental finding during assessment for 
an unrelated childhood illness, typically a respiratory 
complaint. In four patients, splenomegaly without clini-
cal enlargement of the liver led directly to the diagnosis. 
One patient with neuronopathic Gaucher disease was 
identified after the diagnosis had been made in a sibling. 
In all four patients for whom longitudinal growth data 
were available, height velocity improved after enzyme 
infusions started; catch-up growth was accompanied by 
salutary changes in peripheral blood counts, hepatosple-
nomegaly and plasma chitotriosidase activity.
Two patients with neuronopathic Gaucher disease had 
received a bone marrow transplant as a primary inter-
vention at the ages of 18 months and 11 years; the other 
patients are treated by enzyme therapy. Enzyme therapy 
was started at various times – before the age of 1 year to 
41 years of age; median 3 years.
Impaired horizontal saccadic eye movement was pre-
sent in all patients entering the study with neuronopathic 
Gaucher disease; more than 70% also had defective ver-
tical saccadic movements. Strabismus was present in 22 
(> 80%) of the patients (reflecting abducens nerve palsy); 
increased muscle tone and tendon reflexes were noted in 
18 and intention tremor in 14 patients. Myoclonus and 
epilepsy, including myoclonic seizures, occurred in five 
patients. Disease severity, as determined by the modified 
Severity Scoring Tool (mSST) [39, 40], ranged from 0.5 to 
19.5 at recruitment (higher scores indicating more severe 
disease; maximum 36); the mean score was 6.3 ± 5.4.
Patients with neuronopathic Gaucher disease at 
recruitment had non-neurological comorbidities. The 
most frequent were kyphosis (and/or scoliosis) and infil-
trative lung disease—some patients had recurrent res-
piratory symptoms in the absence of a formal diagnosis 
of pulmonary infiltration. Of note, no patients were 
homozygous for the p.Asp448His (D409H) mutation in 
GBA1 and, as expected, none had the associated calcific 
cardiac valve disease nor aorto-coronary involvement.
Other neurological manifestations
Beyond the 27 patients assigned to type 3 (neurono-
pathic) disease at baseline as above, during the prospec-
tive study period, additional patients with neurological 
signs were found (see Fig.  2). Forty patients previously 
Table 2 (continued)
Variables Categories* Entire cohort 
(N = 250) [%]
Children
(N = 26) [%]
Adults
(N = 224) [%]
Gaucher Type 1 
(N = 223) [%]
Gaucher Type 3 
(N = 27) [%]
DXA
Spine Number available 189 15 174 171 18
BMD, g/cm2, 
mean ± SD
0.984 ± 0.150 0.836 ± 0.189 0.997 ± 1.139 0.989 ± 0.144 0.937 ± 0.196
Median (range) 0.982 (0.547–1.446) 0.759 (0.547–1.151) 0.986 (0.695–1.446) 0.982 (0.603–1.446) 0.989 (0.547–1.248)
Total Hip Number 165 3 162 152 13
BMD, g/cm2, 
mean ± SD
0.930 ± 0.153 0.716 ± 0.133 0.935 ± 0.151 0.934 ± 0.153 0.892 ± 0.159
Median (range) 0.924 (0.600–1.276) 0.687 (0.600–0.861) 0.926 (0.607–1.276) 0.923 (0.607–1.276) 0.874 (0.600–1.253)
Femoral Neck Number 165 3 162 152 13
BMD, g/cm2, 
mean ± SD
0.813 ± 0.152 0.615 ± 0.120 0.816 ± 0.151 0.814 ± 0.153 0.793 ± 0.152
Median (range) 0.801 (0.464–1.360) 0.640 (0.485–0.719) 0.804 (0.464–1.360) 0.804 (0.464–1.360) 0.789 (0.485–1.061)
Forearm Number 77 – 77 70 7
BMD, g/cm2, 
mean ± SD
0.658 ± 0.103 – 0.658 ± 0.103 0.660 ± 0.104 0.644 ± 0.090
Median (range) 0.653 (0.458–0.871) – 0.653 (0.458–0.871) 0.654 (0.458–0.871) 0.632 (0.513–0.778)
BMD bone mineral density, DXA Dual-energy X-ray absorptiometry, GD1-DS3 Gaucher disease type 1 severity scoring system, SD standard deviation
*Categorical variables are expressed as frequency [percent]. Continuous variables are expressed as mean ± SD and median (range)
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classified as type 1, non-neuronopathic Gaucher dis-
ease at enrolment, were examined opportunistically by 
a neurologist as a convenience sample. This supplemen-
tary examination included the assessment of saccadic eye 
movements as part of a parallel study and in all but one, 
a video-oculographic assessment was undertaken using 
EyeSeeCam [41]. Twenty-five patients were selected at 
random and 15 were examined because of clinical fea-
tures of severe systemic disease and/or with GBA1 geno-
types recognised to be adverse: L444P, R463C, W184R in 
homozygous or heterozygous form as well as rare alleles 
(including the RecNciI complex variant). Of note, several 
of these potentially adverse genotypes are also present in 
the remaining Gaucherite cohort not yet subject to inde-
pendent re-examination by a neurologist.
As depicted in Fig. 2, of the forty patients in all, 25 had 
a normal clinical examination on review and of these, 
three had abnormal saccades detected by oculography 
and on careful scrutiny, other neurological features (two 
had an undefined cognitive and behavioural phenotype; 
the remaining patient suffered seizures with abnormal 
magnetic resonance brain imaging). Also as shown in 
the figure, fifteen of the forty re-examined patients had 
abnormal neurological signs—two had Parkinson dis-
ease. Development of Parkinson disease, with or with-
out Lewy body dementia, is an uncommon but now 
recognised feature of type 1 Gaucher disease; abnormal 
oculography occurs in Parkinson disease [42]. The thir-
teen (non-Parkinsonian) patients with neurological signs, 
including abnormal ocular signs, may be eligible for reas-
signment to Gaucher disease type 3, since the presence of 
supranuclear ophthalmoplegia with abnormal saccades is 
claimed to be essential for the diagnosis of chronic neu-
ronopathic Gaucher disease [43]. Four of these patients, 
were found to have florid manifestations of type 3 disease 
with additional severe systemic features that included 
kyphosis.
In summary, of the group of forty patients formerly 
classed as having type 1 disease who were later reviewed 
by a neurologist in this study, sixteen were found to 
have neurological signs associated with neuronopathic 
Gaucher disease and two had Parkinson disease. Indi-
vidual GBA1 genotypes in these patients, with totals 
in parenthesis, were: L444P/R463C (4); R463C/Rec-
Nci1 (4); L444P/P266R (1); L444P/P266A   (1); R463C/
IVS2 + 1G (1); R463C/G377R (1); R463C/R257Q (1); 
R463C/R496C  (1); RecNci1/ R262G (1); H311R/R359Q 
(1) (Additional file 1: Table S7).       
Other manifestations
Haematological findings
Within 30  days of enrolment, the mean haemoglobin 
was 139 g/L (range 101–178) and the platelet count was 
189 ×  109/L (range: 39–489). The effect of splenectomy 









25 random; 15 severe features 
Clinically reassessed- including saccades






4 with severe systemic disease
(of these, 1 also with ataxia) 




2 with an undefined 
cognitive/behavioural phenotype





† 2 patients with Parkinson disease not included in analysis of saccades 
Fig. 2 Neurological signs in Gaucher disease type 1. At enrolment, 223 of 250 patients had been classified as non-neuronopathic type 1 Gaucher 
disease and 27 with neuronopathic type 3 Gaucher disease. During the prospective study period, forty patients originally assigned to the type 1 
disease category were subject to re-examination by a neurologist who found central nervous system signs in 15, of whom 13 had type 3 disease 
with clinically evident saccadic abnormalities. Of the 25 patients without clinical neurological signs, based on oculography and other clinical 
features, only 3 meet the criteria for reclassification as type 3 disease  (X2 test with Yates correction, p-value < 0.00001)
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on the platelet count was evident in the splenectomised 
subgroup compared with non-splenectomised patients; 
there was no material difference in haemoglobin concen-
tration (Table 3).
Pulmonary disease
Pulmonary manifestations of Gaucher disease have been 
described but there is a lack of consensus about the 
nature of the pathological process and its classification. 
Eight patients with type 1 disease had pulmonary disease 
for which no other cause could be identified: thoracic 
imaging in this group, revealed bronchiectasis, fibrosis, 
interstitial disease (with nodules and interlobular sep-
tal thickening) and signs of pulmonary hypertension. 
Twenty-two patients with type 3 disease had intermit-
tent respiratory symptoms: eight had recurrent respira-
tory infections or symptoms suggesting asthma; they had 
not undergone more detailed radiological investigation 
(e.g. computerized X-ray tomography). One patient had 
isolated pulmonary hypertension of unknown cause and 
the 13 remaining had bronchial and interlobular septal 
thickening, reticular-nodular shadowing with a ground-
glass appearance on tomographic scans; cystic changes 
also occurred. One patient had recurrent pneumothora-
ces: histology of pulmonary tissue and bronchoalveolar 
lavage from this patient showed Gaucher cell infiltration. 
A further patient suffered pulmonary haemorrhages that 
required therapeutic embolisation. See Table 4.
Hepatic disease
Clinical features of liver disease with abnormal imag-
ing with or without histopathological findings indicat-
ing fibrosis or cirrhosis not clearly attributable to fatty 
infiltration or alcoholic liver disease, were identified in 
fourteen patients (9 with type 1, and 5 with type 3 Gau-
cher disease; Table  4). Eleven of these had been sple-
nectomised and in several, the liver injury had been 
documented before enzyme therapy was started. In these 
14 patients, the median interval between diagnosis of 
liver disease and Gaucher-specific therapy was 5.5 years 
but with a wide range—treatment having started 27 years 
before and up to 8  years after liver disease was recog-
nized. Liver transplantation had been carried out in two 
patients: one had acute hepatic decompensation and the 
other, hepato-pulmonary syndrome. These individuals 
continue to receive enzyme therapy with good effect and 
were alive 19 and 21  years after transplantation. A fur-
ther fourteen patients had structural liver abnormalities 
identified on imaging but a formal diagnosis by biopsy 
has not been made. The abnormalities include irregular-
ity of the hepatic capsule, focal lesions, atrophy, calcifica-
tion, and hepatic infarcts. More detailed studies on the 
hepatic and pulmonary manifestations of patients in the 
Table 3 Laboratory characteristics of the GAUCHERITE cohort and subgroups at recruitment
SD standard deviation
*Continuous variables are expressed as mean ± SD and median (range).




Gaucher Type 1 (N = 223) Gaucher Type 3 (N = 27)
Haemoglobin Number 211 11 200 193 18
g/L, mean ± SD 139.5 ± 13.9 133.7 ± 11.6 139.9 ± 14.0 140.3 ± 13.6 131.3 ± 15.2
Median (range) 139 (101–178) 131 (118–151) 139 (101–178) 139 (101–178) 131 (103–160)
 With spleen Number 157 11 146 146 11
g/L, mean ± SD 140 ± 15 134 ± 12 141 ± 15 141 ± 14 129 ± 17
Median (range) 139 (101–178) 131 (118–151) 140 (101–178) 140 (101–178) 131 (103–160)
 Without spleen Number 54 – 54 47 7
g/L, mean ± SD 137 ± 11 – 137 ± 11 138 ± 11 135 ± 14
Median (range) 138 (116–163) – 138 (116–163) 138 (116–163) 131 (120–153)
Platelet count Number 208 11 197 190 18
109/L, mean ± SD 200 ± 74 229 ± 62 198 ± 74 196 ± 74 244 ± 52
Median (range) 189 (39–489) 213 (151–337) 187 (39–489) 184 (39–489) 234 (147–337)
 With spleen Number 155 11 144 144 11
109/L, mean ± SD 178 ± 56 229 ± 62 174 ± 54 173 ± 53 242 ± 58
Median (range) 175 (39–337) 213 (151–337) 175 (39–321) 175 (39–321) 230 (147–337)
 Without spleen Number 53 – 53 46 7
109/L, mean ± SD 263 ± 82 – 263 ± 82 265 ± 87 248 ± 46
Median (range) 253 (87–489) – 253 (87–489) 253.5 (87–489) 236 (197–318)
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GAUCHERITE cohort will be reported separately and 
where possible this will include a systematic re-evalua-
tion of the neurological findings across the entire cohort.
Malignant disease
Twenty-three patients with type 1 disease (of whom 9 
were splenectomised) had documented cancer (median 
age 62  years, range: 18–83). Of these, > 80% had non-
haematological cancer [7 cutaneous, 4 gastro-intestinal, 
2 breast, 2 nervous system (cerebral meningioma and 
spinal cord tumour), one each of hepatic, renal, genito-
urinary tract and respiratory]. Of the four patients with 
haematological cancer, 3 had myeloma and one, B-cell 
lymphoma—Tables 4, 5 and 6.
Treatment status
Splenectomy
Overall, one quarter of the patients had undergone 
splenectomy (median age of the procedure, 17  years, 
Table 4 Other manifestations of the GAUCHERITE cohort and subgroups at recruitment
SD standard deviation
*Continuous variables are expressed as mean ± SD and median (range)
Variables Categories* Entire cohort 
(N = 250) [%]
Children
(N = 26) [%]
Adults
(N = 224) [%]
Gaucher Type 
1 (N = 223) [%]
Gaucher Type 
3 (N = 27) [%]
Gallstones Yes 79 [32] 1 [4] 78 [35] 75 34] 4 [15]
Age at diagnosis, years, mean ± SD 41 ± 13 16 ± 0 42 ± 12 42 ± 12 35 ± 19
Median (range) 40 (11–66) 16 (16) 40 (11–66) 40 (11–66) 35 (16–55)
Age unknown 5 – 5 5 –
No 171 [68] 25 [96] 146 [65] 148 [66] 23 [85]
Path to diagnosis of gallstones Incidental 43 [54] 1 [100] 42 [54] 40 [53] 3 75]
Symptoms prompted investigations 32 [41] – 32 [41] 31 [41.5] 1 [25]
Unknown 4 [5] – 4 [5] 4 [5.5] –
Cholecystectomy Yes 37 [15] 1 4] 36 [16] 35 [16] 2 [7]
Age at cholecystectomy, years, 39 ± 13 16 ± 0 39 ± 12 39 ± 12 35 ± 28
mean ± SD
Median (range) 37 (16–69) 16 37 (18–69) 37 (18–69) 35 (16–55)
Missing age 1 – 1 1 –
No 213 [85] 25 [96] 188 [84] 188 [84] 25 [93]
Cancer Yes 23 [9] – 23 [10] 23 [10] –
Haematological 4 – 4 (17%) 4 (17%) –
Non-haematological 19 – 19 (83%) 19(83%) –
Age at diagnosis, years, mean ± SD 59 ± 15 – 58 ± 15 59 ± 15 –
Median (range) 62 (18–83) – 62 (18–83) 62 (18–83) –
No 227 [91] 26 [100] 201 [90] 200 [90] 27 [100]
Hepatic
Disease
Yes 14 [6] – 14 [6] 9 [4] 5 [19]
Age at diagnosis, years, mean ± SD 40 ± 17 – 40 ± 17 47 ± 12 27 ± 18
Median (range) 41 (6–75) – 41 (6–75) 45 (37–75) 24 (6–55)
No 236 [94] 26 [100] 210 [94] 214 [96] 22 [81]
Pulmonary disease Yes 29 12] 8 31] 21 [9] 7 [3] 22 [81.5]
Age at diagnosis, years, mean ± SD 19 ± 22 5 ± 2 24 ± 24 39 ± 28 12 ± 15
Median (range) 8 (1–72) 5 (2–9) 14 (1–72) 51 (4–72) 6 (1–57)
No 221 [88] 18 [69] 203 [91] 216 [97] 5 [18.5]
Table 5 Splenectomy and non-haematological cancer
*Proportion = Non-haematological cancer/Total size




Total size Proportion* P-value†
With spleen 10 188 0.053 0.03
Without spleen 9 62 0.145
Total 19 250
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range: 1–58). The spleen has been removed in one third 
of those classified with type 3 Gaucher disease—in all 
instances in infancy and childhood (median age 5 years, 
range: 1–15). Three quarters of the splenectomies had 
been carried out before 1992–3, when tissue-derived 
enzyme therapy first became available in the European 
region before full regulatory approval: alglucerase was 
marketed from 1994 in Europe; the recombinant prod-
uct, imiglucerase, was approved for marketing in 1997, 
followed by velaglucerase alfa in 2010 [20, 44].
It is noteworthy that of the 15 patients who under-
went splenectomy after 1993, cytopenia was an unu-
sual indication. In eight patients, the spleen had been 
removed for diagnostic purposes (e.g. suspected malig-
nancy) before referral to the specialist service; in a 
further three, the indication post-traumatic splenic 
rupture. Splenectomy was carried out for other rea-
sons in three patients: inadequate responses to enzyme 
therapy with concern about bleeding risk, management 
of splenic infarction—and for an unknown indication in 
one patient.
Haematopoietic stem‑cell transplantation
Two patients (1 man aged 46 and 1 woman, aged 
30  years at recruitment) in the study had undergone 
haematopoietic stem cell transplantation as a pri-
mary intervention for Gaucher disease. Both share 
the p.Leu483Pro (L444P) homozygous genotype and 
have a classical “Norrbottnian” type 3 phenotype [6, 
8, 45]. Transplantation from HLA-matched related 
donors was carried out in childhood (aged 11  years 
and 18 months, respectively). Splenectomy was under-
taken before the procedure: growth and haematological 
parameters responded favourably—although kyphosis 
and neurological signs have slowly progressed in these 
patients. These surviving patients are among six trans-
planted in UK as originally pioneered by Hobbs and 
colleagues [46, 47].
Enzyme and substrate‑reduction therapies
Two hundred and forty-three patients were receiving 
specific treatment for Gaucher disease within 6 months 
of recruitment to the study: velaglucerase alfa was given 
to 141 patients, imiglucerase to 89, miglustat to 4 and 
eliglustat to 7 (Additional file 1: Table S6). At the time 
of writing, 65 patients are taking eliglustat and will be 
the subject of follow-up studies related to safety, toler-
ability and efficacy based on this cohort. Three patients 
were taking enzyme therapy combined with substrate-
reduction therapy: velaglucerase alfa and miglustat in a 
patient with type 1 disease, and imiglucerase with eli-
glustat in two patients with type 3 Gaucher disease.
Treatment‑related adverse events
Sixty-eight treatment-related adverse events (of 
which 36 were in patients receiving miglustat) had 
been reported in 43 patients. None of the reactions 
was life-threatening. As a result of adverse events, 25 
users of miglustat had stopped this treatment. Seven 
patients receiving enzyme therapy stopped temporarily 
(1–4  months) and one permanently, switching to oral 
therapy (miglustat for 25  months and then eliglustat 
after a further 53  months). The six other patients all 
returned to enzyme therapy, one initially returned to 
alglucerase (in 1993) and two patients receiving talig-
lucerase alfa returned to either imiglucerase or velaglu-
cerase. These latter are the only preparations currently 
approved in the UK. In the cohort, infusion reactions 
have been recorded in two patients: one developed 
migraine and having developed sensitivity to all three 
recombinant enzyme preparations, the other switched 
to oral therapy (eliglustat) after study lock.
Bone specific therapies
Seventy-five patients had received anti-resorptive and/
or anabolic drugs before recruitment. Within 6 months 
of enrollment, 94 patients in all had received a medi-
cation to treat or prevent skeletal disease (i.e. supple-
mental calcium and/or vitamin D, anti-resorptive or 
anabolic drugs). Seventy-nine patients had received cal-
cium alone or in combination with vitamin D; 14 had 
received bisphosphonates alone or in combination with 
calcium and/or vitamin D supplements and one patient 
had received anabolic treatment in combination with 
calcium and vitamin D supplements (Additional file  1: 
Table S6).
Effect of splenectomy on skeletal manifestations
The occurrence of symptomatic osteonecrosis was 
strongly associated with splenectomy (Fig. 3A): control-
ling for gender, the hazard/intensity ratios for first and 
subsequent events were about 3 times greater in patients 
after splenectomy (p < 0.0001).
Table 6 Splenectomy and haematological cancer
*Proportion = Haematological cancer/Total size
† Fisher’s Exact test P-value
Group Haematological 
cancer
Total size Proportion* P-value†
With spleen 4 188 0.021 0.58
Without spleen 0 62 0
Total 4 250
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Splenectomy also influenced fracture risk (Fig.  3B). 
Controlling for gender, the hazard ratio for first fragility 
fracture in patients after undergoing splenectomy was 
nearly three-fold greater than those in whom the spleen 
was, or is intact (p = 0.01). Splenectomy was additionally 
associated with an approximately sixfold greater risk of 
repeated fragility fractures (p < 0.0001). Figure  3 shows 
the temporal relationship to first skeletal events and the 
association of splenectomy, from diagnosis onwards: the 
two panels compare events for osteonecrosis and fragil-
ity fracture—depicting the interaction of age and gender 
in fragility fractures, in which a component risk due to 
the menopause in women would be predicted. Risk of 
osteolytic lesions and the occurrence of orthopaedic pro-
cedures were about 2.7- and twofold respectively higher 
after splenectomy, when controlled for gender (p = 0.12 
and p = 0.01, respectively).
Symptomatic osteonecrosis and fracture in relation 
to Gaucher‑specific therapy
Data from two hundred and forty-six patients were 
available for analysis of the relationship between the 
skeletal events and introduction of molecular therapies 
for Gaucher disease. Fifty-one first episodes of sympto-
matic osteonecrosis were documented in 242 patients 
when they were not receiving Gaucher-specific therapy 
(2136 person-years of follow-up), whereas 13 first events 
occurred in 180 patients after treatment, which was 
initially enzyme therapy (2493 person-years of follow-
up), hazard ratio 0.2, p < 0.001. At the time of data lock, 
too few patients have been exposed to the other spe-
cific interventions (marrow transplantation or substrate 
reduction therapy) for such analysis (Fig. 4). Age at which 
treatment began had no detectable effect.
In an Andersen-Gill analysis of 120 repeated events, 
the rate of symptomatic osteonecrosis was also reduced 
after specific treatment was started (hazard ratio 0.45, 
p < 0.001) and again there was no age effect. In contrast, 
neither the time to first fragility fracture nor hazard of 
repeated fragility fractures was associated with any, or 
all of the combined specific treatments, nor was there an 
effect of age at which treatment started.
Skeletal complications persist in patients receiving 
bone‑specific treatment
Males with Gaucher disease who had treatment given 
to improve bone density, on average had a lower fragil-
ity fracture rate (p < 0.05) and incidence of lytic lesions 
(p < 0.01) compared with females receiving bone modify-
ing treatment. When followed over 15 years, the average 
fracture rate for males was 14.8 (95% confidence interval 
6.8 to 32.6) per 100 person-years; the corresponding rate 
for females was 63.5 (43.5 to 92.7).
Discussion
In the group of more than eighty inborn lysosomal dis-
orders, Gaucher disease is unique in its susceptibility to 
treatments and with sustained investment, the trans-
formative efficacy of molecular therapies sets this ultra-
rare disorder alongside haemophilia and cystic fibrosis in 
Fig. 3 Cumulative hazard for first osteonecrosis event and fragility fracture. Controlling for gender, the hazard or risk of having a first osteonecrosis 
event (A) and first fragility fracture (B) after presentation of Gaucher disease was greater in patients who had splenectomy (hazard ratio of 3.32 [95% 
CI 1.74–5.00; p < 0.001] and 2.83 [95% CI 1.33–5.99; p = 0.01], respectively). Horizontal axis shows years after presentation with Gaucher disease
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the Pantheon of orphan diseases. Biotechnological inno-
vation has generated a diverse selection of drugs with dis-
tinct modes of action and indications. The competitive 
success of these ventures and marketing exclusivity of 
high-cost orphan drugs, mandate the need for independ-
ent therapeutic research that includes real-world data.
As in other advanced economies, most patients with 
Gaucher disease in the United Kingdom have received 
specific treatment but in the adults reported here, access 
to molecular therapies was often deferred until long 
after diagnosis. As a consequence, irreversible injury, 
especially to the skeleton and larger joints, became an 
inevitable burden. To appraise new treatments for this 
heterogeneous and chronic condition, powerful systems 
to collate, hold and comprehensively analyse extensive 
long-term data are needed.
GAUCHERITE is a platform concept with a national 
cohort of patients that seeks (1) to determine clinical 
burden; (2) characterize the clinical manifestations by 
in-depth phenotyping and (3) ultimately optimize man-
agement by therapeutic stratification of Gaucher dis-
ease. We focused principally on the skeletal aspects but 
also indicate the potential importance of timely recog-
nition of neuronopathic features, which are associated 
with adverse progression of the bone disease. While no 
effective therapy for the neurological manifestations is 
as yet available,  molecular therapies have salutary sys-
temic  effects   which include manifestations in bone: 
nonetheless, persistent bone pain and disabling skeletal 
complications remain dominant   unmet needs in   many 
patients [48].
Our study is aligned to current stratification method-
ology [30]: use of longitudinal data of sufficient depth 
enables the effects of orphan drugs to be analysed even 
in a rare disease. Our approach has been validated, since 
patients were readily stratified in respect of two broad 
interventions: (1) splenectomy, a palliative measure to 
reduce the risk of bleeding and infection due to pancyto-
penia, and (2) introduction of molecular therapies.
In the era before specific therapies became available, 
splenectomy was required to ameliorate severe hyper-
splenism with the risk of life-threatening haemorrhage: 
however the procedure is strongly associated with recur-
rent osteonecrosis and, as shown here, also fragility frac-
tures. Post-splenectomy fractures occur with markedly 
different trajectories according to gender—attributable 
to additional effects of osteoporosis at the menopause. 
The procedure signals a clinically distinct subgroup of 
patients with Gaucher disease with a high demand for 
orthopaedic services. As to cause and effect, we note that 
a forerunner of this study conducted in the UK popula-
tion, identified a temporal relationship of osteonecrosis 
to the immediate years after splenectomy, indicating a 
causal relationship [49–54].
Mechanistic explanations for the diverse consequences 
of splenectomy include: (1) after the procedure, a greater 
burden of glycosphingolipids derived from the destruc-
tion of blood cells will fall on liver macrophages (Küpffer 
cells) and bone marrow. Greater encroachment by 
pathological macrophages will also induce greater local 
pro-inflammatory cytokine and chemokine release. We 
suggest that this will have adverse effects on the capil-
lary network at junctional zones related to the growth 
plate and enhance the pathological accumulation of 
β-glucosylceramide a key ligand, of the mincle protein 
in macrophages and related osteoclasts [14, 15]. Poor 
perfusion will increase the risk of local ischaemia to the 
bone marrow; (2) splenectomy has multiple effects on 
the formed elements of the blood and increased viscosity 
and platelet aggregation index induces a thrombotic ten-
dency [55]. Increased platelet numbers consequent upon 
the abrupt decrease in splenic pooling may also increase 
the risk of osteonecrosis; splenectomy is likely to amplify 
the changes in red-cell deformability due to alterations in 
the lipid composition of red-cell membranes [56]. Finally, 
increased red-cell rigidity will potentiate the effect of 
removing the spleen on the marrow compartment, since 
Fig. 4 Cumulative hazard for first osteonecrosis event according to 
treatment status. The hazard or risk of having a first osteonecrosis 
event after presentation of Gaucher disease was significantly lower 
after starting enzyme replacement therapy (ERT) than before (hazard 
ratio of 0.20; 95% CI 0.11–0.38; p < 0.001). The effects of substrate 
reduction therapy (SRT) and bone marrow transplantation (BMT) 
was difficult to assess owing to the low sample size (nine and two 
patients received SRT or BMT as first treatment, respectively). Of the 
two patients with BMT, one had their first episode of osteonecrosis 
after the procedure. Horizontal axis shows time in years after 
presentation of Gaucher disease
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by analogy with sickle-cell disease, it will impair the 
deformability and flow properties of red cells within the 
microcirculation at watershed regions of oxygen and 
nutrient supply in long bones [57].
The greatly increased hazard of fragility fractures 
showed an incident pattern over time that differs 
between men and women: neither phenomenon has been 
reported. Although splenectomy in Gaucher disease is 
known to be associated with low bone mineral density 
[58], in this respect it  resembles the effect of hyposplen-
ism in sickle-cell anaemia, in which bone mineral density 
is greatly reduced [59]. Here we show a strong associa-
tion with fragility fractures (Table 7 and Fig. 3). Of the 62 
patients lacking a spleen, 21 had sustained multiple fra-
gility fractures and 38 had developed osteonecrosis; these 
data compare with 16 and 38 of 188 Gaucher patients 
who had intact spleens, respectively. We argue that the 
link with the three-fold increased hazard of fragility frac-
tures identified here is clinically important. Since com-
pletion of our analysis, investigation of an international 
registry of type 1 Gaucher patients has recently reported 
a multivariate analysis of fractures in three age cohorts 
among patients with known splenectomy status and at 
least one skeletal assessment on treatment (3216 of 6422 
patients) [60]. Of note, a greater proportion of those 
splenectomized before enzyme treatment (with alglu-
cerase or imiglucerase), had fractures (56% greater risk 
of fracture post-splenectomy). The authors state that for 
patients aged 50 years or older when the therapy was first 
given, the analysis may have been affected by the exclu-
sion of those who had suffered fractures during the long 
interval between the date of splenectomy and starting 
enzyme. Nonetheless in their   report, the fracture risk 
attributed to the procedure was found only statistically 
significant (p = 0.039) in adults aged between 18 and 
50 years at the time enzyme treatment started.
The cause is not obvious and may either be a direct 
or indirect consequence of the procedure. We pro-
pose that rapidly progressive inflammatory disease with 
indications for early splenectomy—especially in young 
patients not promptly diagnosed and thus not optimally 
treated—may be the explanation. Florid Gaucher disease 
activity in childhood is a chronic inflammatory state that 
stunts growth and delays puberty—not only is modelling 
impaired with manifest osseous disease as above, but the 
achievable peak mass of bone is also decreased.
Splenectomy has potential consequences for the skele-
ton beyond osteonecrosis, risk of fracture and, possibly a 
trend towards more frequent osteolytic lesions. Since the 
risk of requiring orthopaedic surgery is also much greater 
in patients whose spleen has been removed (p = 0.01), 
the susceptibility to microbial infection and osteomyeli-
tis (which preferentially affects injured bone—see Addi-
tional file 2: Fig. S1B) is likely to be greater. Overall, the 
findings reinforce the need for vigilant long-term moni-
toring of bone health in patients with Gaucher disease 
who have undergone splenectomy.
Splenectomy has other strong associations with clinical 
behaviour in this condition: there was a marked associa-
tion with liver disease [61], with or without pulmonary 
disease, as has been previously reported [62]. Indeed, 
most of the patients with chronic liver disease, including 
manifest cirrhosis, who had  interstitial lung disease or 
pulmonary hypertension, had had their spleen removed. 
Table 7 Impact of splenectomy on skeletal manifestations since presentation of Gaucher disease
Origin: Gaucher disease presentation
*Event rate was estimated using Andersen-Gill method.
Hazard ratio P-value [95% CI]
1st fragility fracture Splenectomy 2.83 0.01 1.33 5.99
N = 247 Gender effect 1.04 0.91 0.52 2.07
Multiple fragility fractures* Splenectomy 5.78 <0.0001 2.32 14.42
N = 247 Gender effect 0.59 0.17 0.28 1.24
1st osteonecrosis Splenectomy 2.95 <0.0001 1.74 5.00
N = 246 Gender 0.80 0.37 0.48 1.31
Osteonecrosis events* Splenectomy 3.32 <0.0001 1.98 5.56
N = 246 Gender effect 0.95 0.83 0.59 1.53
Presence of Erlenmeyer flask deformity Splenectomy 0.98 0.95 0.59 1.64
N = 248 Gender effect 0.80 0.34 0.50 1.27
Presence of lytic lesions Splenectomy 2.70 0.12 0.76 9.52
N = 248 Gender effect 0.26 0.08 0.06 1.16
Orthopaedic surgery Splenectomy 1.99 0.01 1.15 3.44
N = 244 Gender effect 0.84 0.52 0.50 1.41
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An unexpected finding was the greater frequency of non-
haematological malignancies in patients after removal 
of the spleen: nine of 62, compared with 10 of 188 in the 
spleen-intact group (p < 0.03), Table 5. These differences 
are not explained by age distribution but confirm in our 
population, findings reported in other relatively small 
patient groups [63–66]. The possible effect of splenec-
tomy on the development of various cancers in Gaucher 
disease has been recently reviewed [65] but the mecha-
nism remains unclear [67]. We contend that these find-
ings merit further exploration, particularly given the 
role of pathological sphingolipids in cell death, immune 
recognition and proliferation. That all four patients with 
haematological cancers were among the non-splenec-
tomised group in our cohort, is a tantalizing matter of 
record.
Two hundred and forty-three patients were receiv-
ing a specific molecular therapy for Gaucher disease at 
the time of recruitment; in most cases enzyme therapy 
(velaglucerase alfa or imiglucerase) was used, but eleven 
patients were treated with substrate reduction therapy 
(eliglustat or miglustat). Three had combined therapies 
(eliglustat and imiglucerase; miglustat and velaglucerase 
alfa). At the time of writing, 65 patients, more than one 
quarter of the adult patients with type 1 Gaucher disease, 
are treated with the orally active, systemic substrate-
reducing agent, eliglustat.
Specific treatment for Gaucher disease can reverse 
bone marrow infiltration, cytopenia and visceromegaly 
and ameliorate symptoms with improved quality of life. 
However, persistent skeletal pain is a notorious feature 
and an important cause of disability [48, 49, 68–70]. In 
this cohort, despite the emergence of molecular thera-
pies, bone pain was present in more than half of the 
patients at enrolment, indicating that many UK patients 
had skeletal disease established before the interventions 
became generally available [49, 52]. Many also—espe-
cially women—had persistent fragility fractures, oste-
onecrosis and lytic lesions requiring orthopaedic surgery. 
Nonetheless, it is clear that the introduction of specific 
treatments exerted a protective effect on the disabling 
and painful consequences of osteonecrosis. In this study, 
disease-modifying therapy for Gaucher disease had no 
effect on fracture rate: this might be explained by the 
arrested and thus premature attainment of peak bone 
mass which cannot be further enhanced. As a result, the 
risk of fracture would be more resistant to modification. 
We specifically explored the effect of the age at which 
treatment started on either osteonecrosis or fracture, in 
the era of specific therapy but no association was found 
in this cohort. This might have resulted from the interac-
tion of two opposing effects: once diagnosed in children 
and young adults, when the disease tends to be severe, 
early treatment is available to arrest its progress; while in 
older adults the condition can be severe, the later the age 
at which treatment is instituted may also imply intrinsi-
cally milder disease. In general, however, the interval 
between diagnosis and starting specific treatment for 
Gaucher disease is confirmed to be an important deter-
minant of therapeutic outcome in the skeleton [49, 52]. 
The unequivocal preventative effects of enzymatic aug-
mentation and other interventions   on osteonecrosis 
events, make it clear that the course of this disease can 
now be favourably modified.
Formerly, the diagnosis of patients with type 1 disease 
was mainly in adult life and often long after the onset of 
symptoms; those designated as type 3 Gaucher disease 
were nearly all identified in childhood. While this distinc-
tion reflects the often aggressive presentation of Gaucher 
type 3 disease, with greater awareness and improved ser-
vices in the molecular era, the  trend has not continued. 
Ostensibly non-neuronopathic disease is increasingly 
recognised in children and, as we show, more subtle neu-
ronopathic forms of the disease may develop in adults. 
Careful follow-up of Gaucher patients in Japan  who 
were homozygous for the L444P GBA1 allele but with 
non-neuronopathic disease in childhood, demonstrated 
the onset and evolution of neuronopathic features over 
time [71]. In the European and North-American litera-
ture [68–70, 72], as here, most patients  are considered 
to have ‘non-neuronopathic’ rather than neuronopathic 
disease, despite the additional long-term risk of develop-
ing Parkinson disease and/or Lewy body dementia with 
accompanying neuropathology [18].
We uncovered more patients with features compat-
ible with neuronopathic disease than expected in the UK 
population; these patients appear to be at a greater risk of 
developing early skeletal as well as other systemic mani-
festations of Gaucher disease [13, 73, 74]. Twenty-seven 
of the 250 were noted originally to have neuronopathic 
disease but a further 16 had features indicative of type 
3 disease based principally on proven ophthalmic signs, 
suggesting an evolving pattern in some patients. The 
findings point to greater phenotypic variation than gen-
erally reported in the literature and further question the 
wisdom of assigning a subtype and phenotypic classifica-
tion to a patient with Gaucher disease without neurologi-
cal review—especially within the early years of diagnosis. 
With this in mind and prompted by the initial findings in 
a limited sample group, we plan systematically to re-eval-
uate the neurological features of the entire cohort. The 
need for intensified clinical monitoring mandated by the 
high risk of skeletal and other systemic manifestations 
in patients with neuronopathic disease will allow timely 
disease-modifying therapy to be introduced [33, 43]. It is 
now clear that diverse neurological features are found in 
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all categories of Gaucher disease and represent a burden 
of illness globally which has not been fully appreciated in 
the Western and anglophone literature [2, 8].
The nature of this cohort, in which most patients were 
receiving specific treatment at the time of enrolment, 
required use of an analytical method that enables thera-
peutic stratification based on repeated evaluation of the 
outcomes and complications of the disease over time 
[44, 60]. Despite the great rarity of Gaucher disease, 
many clinical publications have depended on data in 
registries supported by the biopharmaceutical industry, 
which naturally place emphasis on particular products 
and help to meet the requirements imposed by regula-
tory agencies. We reasoned that an established but more 
independent National cohort would be needed to stratify 
clinical outcomes and disease behaviour in a period of 
intense commercial therapeutic development and would 
foster further research. We suggest that the study dif-
fers importantly from the international commercial reg-
istries and contend that the GAUCHERITE cohort has 
advantages which, in toto, also differentiate it from the 
pioneering and instructive non-commercial initiatives 
of investigators in individual countries such as the Neth-
erlands, Spain and France [69, 70, 72, 73]: (1) the study 
represents a long-established national disease population 
in patients attending specialist centres at state-funded 
University hospitals which, unlike private healthcare, 
are obliged to follow agreed clinical guidelines and uni-
form practices; (2) all approved treatments and clinical 
services are funded by the UK National Health Service; 
(3) clinical investigators are unbiased with respect to the 
manufacturer of molecular therapies – all disease-related 
drugs and nutritional supplements and their doses are 
captured; (4) the study and clinical research programme 
is subject to a single overarching national ethical review 
and approval process; (5) high-level data completion 
across the cohort without incentives such as third-party 
remuneration to investigators; (6) the study requires 
detailed completion of structured protocols for clinical 
history and physical findings with serial patient-reported 
outcomes, including formal QOL questionnaires; (7) a 
single database, with mass storage of > 2500 variables, 
holds all radiological images of radiology and DXA scan-
ning including linked narrative reports downloaded from 
the study centres; (8) use of the data is   governed by an 
independently approved Data Management policy, allow-
ing investigators access to anonymised data and curated 
serial Biobanked blood and tissue samples linked to the 
relational GAUCHERITE database; (9) the research and 
publication policy is governed by an independent man-
agement oversight committee chaired by a senior patient 
advocate and charity founder.
Scrutiny of this large dataset emphasises the value of 
systematic phenotyping by investigators with long-term 
specialist engagement in the care of patients affected by 
an ultra-rare disease. The strength of the cohort is that 
it spans the pre-treatment era and subsequent inter-
ventions. The extent and depth of data is founded on 
repeated year-on-year serial tests (median 26) and uti-
lises comprehensive records in a relational database that 
allow linear analysis using the repeated mixed measures 
model of individual timed events. The transformative 
effects of the therapies combined with intense phenotyp-
ing, time-to-event analysis and historical depth in diverse 
domains of the disease are also advantages.
Conclusions
The GAUCHERITE cohort, which comprises 85% of all 
patients known to have Gaucher disease in the United 
Kingdom, represents an independent, data-rich platform 
to study the epidemiology and course of this heterogene-
ous disorder. We show that the database is a source of 
information that allows clinical effectiveness and appro-
priateness of care to be investigated in real-world clini-
cal practice; the data can moreover be explored in depth 
by stratifying patients according to potentially divergent 
treatment effects. Finally, the cohort is an opportune 
resource by which to appraise newly introduced and 
future therapies.
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